Sign In
Buy XFOR
$4.04
-0.0700 (-1.70%)
At Close: Jun 02, 2026
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
08:01am, Wednesday, 02'nd Aug 2023
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of
X4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Earnings Call Transcript
07:35pm, Saturday, 06'th May 2023
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Dr. Paula Ragan - President and CEO Adam Mostafa -
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
08:01am, Wednesday, 26'th Apr 2023
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of
X4 Pharmaceuticals shares lift as investors await new data from WHIM syndrome study
10:58am, Wednesday, 12'th Apr 2023
X4 Pharmaceuticals, the Boston-based drug developer, saw its stock trading higher on Wednesday as investors gear up for new results from a Phase 3 trial of its oral cxcr4 antagonist, mavorixafor, for
X4 Pharmaceuticals: Chronic Neutropenia Might Finally Have Met Its Match
04:29am, Wednesday, 12'th Apr 2023
Positive P3 results of mavorixafor for first-ever treatment of WHIM syndrome with possible BLA approval in 1H 2024. A large chronic neutropenia market could see their first approved drug in over 30 ye
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases o
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock
01:16pm, Tuesday, 31'st Jan 2023
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Penny Stocks To Buy: 6 Insider Picks Before 2023
12:24pm, Wednesday, 21'st Dec 2022
Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny
X4 Pharmaceuticals, Inc. (XFOR) Q3 2022 Earnings Call Transcript
01:55pm, Saturday, 05'th Nov 2022
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2022 Results Conference Call November 3, 2022 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - Chief Executive Officer Diego Cadavi
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 04'th Nov 2022 GlobeNewswire Inc.
BOSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of t
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10:05am, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
Following positive mavorixafor Phase 1b data release in multiple chronic neutropenic disorders, X4 continues to look forward to top-line results from its pivotal Phase 3 trial in WHIM syndrome in the
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
12:00pm, Wednesday, 26'th Oct 2022 GlobeNewswire Inc.
A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022
BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of t
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
04:06pm, Friday, 30'th Sep 2022 Benzinga
Gainers
Ainos, Inc. (NASDAQ: AIMD) shares surged 55.1% to $2.1411 after the company reported results from the additional preclinical study of its low-dose oral interferon formulation against Omicron.
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
09:10am, Wednesday, 28'th Sep 2022 Benzinga
Gainers
Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares climbed 106.3% to close at $9.15. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducte
